Constantino Michael T. 4

What Happened
Michael T. Constantino, a director of Humacyte, was granted 80,000 derivative shares (reported as an award/option) on 2026-06-11. The filing lists an acquisition price of $0.00 and a total reported value of $0 for the grant — the instrument is reported as a derivative (option-like) award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12.
• Transaction type/code: Award/Grant (A), derivative security.
• Amount: 80,000 shares; reported price: $0.00; reported value: $0.
• Vesting/Exercise schedule (footnote F1): first 25% becomes exercisable on June 11, 2027; thereafter 1/48 of the option vests on the 11th of each month through June 11, 2030.
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: appears timely (filed the day after the transaction).

Context
This was a compensatory grant to a director (typical for board compensation) and is a derivative award that vests over time — not an immediate buy or sale of stock. Because the award vests in the future, it does not represent an immediate market purchase or sale; it simply gives the director potential future exposure contingent on vesting/exercise terms. The filing reports a $0.00 per-share figure for the award; for details on valuation, tax treatment, or whether these are options vs. RSUs, review the company’s proxy/compensation disclosures.